Agios Pharmaceuticals Beheer
Beheer criteriumcontroles 4/4
De CEO Agios Pharmaceuticals is Brian Goff, benoemd in Aug2022, heeft een ambtstermijn van 2.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.42M, bestaande uit 23.4% salaris en 76.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde $ 4.37M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 7.6 jaar.
Belangrijke informatie
Brian Goff
Algemeen directeur
US$3.4m
Totale compensatie
| Percentage CEO-salaris | 23.4% |
| Dienstverband CEO | 2.3yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 7.6yrs |
Recente managementupdates
Recent updates
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$674m |
| Jun 30 2024 | n/a | n/a | -US$365m |
| Mar 31 2024 | n/a | n/a | -US$353m |
| Dec 31 2023 | US$3m | US$798k | -US$352m |
| Sep 30 2023 | n/a | n/a | -US$220m |
| Jun 30 2023 | n/a | n/a | -US$210m |
| Mar 31 2023 | n/a | n/a | -US$218m |
| Dec 31 2022 | US$12m | US$308k | -US$232m |
Compensatie versus markt: De totale vergoeding ($USD 3.42M ) Brian } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.55M ).
Compensatie versus inkomsten: De vergoeding van Brian is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Brian Goff (55 yo)
2.3yrs
Tenure
US$3,416,453
Compensatie
Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. from June 2024. He is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.42m | 0.14% $ 4.4m | |
| Chief Financial Officer | 2.2yrs | US$1.21m | 0.035% $ 1.1m | |
| Corporate Secretary & Chief Legal Officer | 2.8yrs | US$1.93m | 0.028% $ 869.8k | |
| Chief Medical Officer and Head of Research & Development | 3.2yrs | US$2.87m | 0.077% $ 2.4m | |
| Chief Commercial Officer | 1.8yrs | US$3.73m | 0.023% $ 733.3k | |
| Founder | no data | US$333.51k | geen gegevens | |
| Founder | no data | geen gegevens | geen gegevens | |
| Founder | no data | geen gegevens | geen gegevens | |
| Founder | no data | geen gegevens | geen gegevens | |
| VP, Controller & Principal Accounting Officer | 3.3yrs | geen gegevens | 0.0027% $ 84.4k | |
| Chief Technical Operations Officer | 7.4yrs | geen gegevens | geen gegevens | |
| Vice President of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AGIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.42m | 0.14% $ 4.4m | |
| Chair of the Board of Directors | 6.9yrs | US$447.25k | 0.25% $ 7.8m | |
| Independent Director | 1.4yrs | US$663.68k | 0.0035% $ 109.3k | |
| Member of Scientific Advisory Board | 8.3yrs | US$302.85k | geen gegevens | |
| Member of Scientific Advisory Board | 15.8yrs | geen gegevens | geen gegevens | |
| Lead Independent Director | 9.9yrs | US$440.95k | 0.013% $ 418.3k | |
| Independent Director | 15.3yrs | US$417.25k | 0.83% $ 26.4m | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 16yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 3.8yrs | US$3.21m | geen gegevens | |
| Independent Director | 2.3yrs | US$419.91k | 0.014% $ 442.6k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
7.6yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AGIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.6 jaar).